North America
While ALRN-6924 is first being tested in breast and lung cancer, the firm believes it can help patients with any type of p53-mutated cancer avoid chemo toxicities.
Day One Biopharmaceuticals Begins Combination Portion of Trial in MAPK-Altered Tumors
Following on a monotherapy study initiated last year, the new study will combine two of Day One's investigational compounds: a Raf kinase inhibitor and a MEK inhibitor.
Seagen Going After Tukysa, Herceptin Combo Approval in HER2-Positive Colorectal Cancer
The company plans to seek accelerated approval for the regimen after seeing a 38 percent objective response rate in the MOUNTAINEER trial.
The lead investigators have also spun out a company, Isabl, aiming to make the approach available to the broader community.
The firm's next move will be to pit aumolertinib against AstraZeneca's Tagrisso, the new standard of care in EGFR-mutated NSCLC.
May 19, 2022
Inceptor Bio Raises $37M in Series A Financing
May 17, 2022
Vyriad Raises $29.5M in Extended Series B Financing
May 17, 2022